PL185442B1 - Środek farmaceutyczny o działaniu immunologicznym i psychotropowym, jego postać terapeutyczna oraz zastosowanie - Google Patents
Środek farmaceutyczny o działaniu immunologicznym i psychotropowym, jego postać terapeutyczna oraz zastosowanieInfo
- Publication number
- PL185442B1 PL185442B1 PL96316416A PL31641696A PL185442B1 PL 185442 B1 PL185442 B1 PL 185442B1 PL 96316416 A PL96316416 A PL 96316416A PL 31641696 A PL31641696 A PL 31641696A PL 185442 B1 PL185442 B1 PL 185442B1
- Authority
- PL
- Poland
- Prior art keywords
- proline
- polypeptide
- val
- molecular weight
- amino acid
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 10
- 230000000506 psychotropic effect Effects 0.000 title claims description 10
- 230000001900 immune effect Effects 0.000 title claims description 9
- 230000001225 therapeutic effect Effects 0.000 title claims description 6
- 238000000034 method Methods 0.000 title description 6
- 230000001747 exhibiting effect Effects 0.000 title 1
- 230000004957 immunoregulator effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 7
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 210000003022 colostrum Anatomy 0.000 claims description 15
- 235000021277 colostrum Nutrition 0.000 claims description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- 241001494479 Pecora Species 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 12
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 229940024606 amino acid Drugs 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 7
- 239000004473 Threonine Substances 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- 235000004279 alanine Nutrition 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- 235000003704 aspartic acid Nutrition 0.000 claims description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 7
- 235000018417 cysteine Nutrition 0.000 claims description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
- 235000013922 glutamic acid Nutrition 0.000 claims description 7
- 239000004220 glutamic acid Substances 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 7
- 229960000310 isoleucine Drugs 0.000 claims description 7
- 229930182817 methionine Natural products 0.000 claims description 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 7
- 239000004474 valine Substances 0.000 claims description 7
- 108010020048 valyl-glutamyl-seryl-tyrosyl-valyl-prolyl-leucyl-phenylalanylproline Proteins 0.000 claims description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 6
- 230000000686 immunotropic effect Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 235000021309 simple sugar Nutrition 0.000 claims description 4
- 108010002212 colostrinine Proteins 0.000 abstract description 51
- 208000017667 Chronic Disease Diseases 0.000 abstract description 3
- 210000003169 central nervous system Anatomy 0.000 abstract description 2
- 210000000987 immune system Anatomy 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 description 15
- 102000014150 Interferons Human genes 0.000 description 15
- 239000002158 endotoxin Substances 0.000 description 14
- 229920006008 lipopolysaccharide Polymers 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 102000003390 tumor necrosis factor Human genes 0.000 description 12
- 229940079322 interferon Drugs 0.000 description 11
- 230000006698 induction Effects 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000004700 fetal blood Anatomy 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- 208000012186 Alzheimer disease 3 Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031957 HIV carrier Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960003718 diatrizoate sodium Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940067003 orabase Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
Priority Applications (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL96316416A PL185442B1 (pl) | 1996-10-03 | 1996-10-03 | Środek farmaceutyczny o działaniu immunologicznym i psychotropowym, jego postać terapeutyczna oraz zastosowanie |
| TR1999/01022T TR199901022T2 (xx) | 1996-10-03 | 1997-10-03 | Kolostrinin ve kullan�mlar� |
| RU99109093/15A RU2217152C2 (ru) | 1996-10-03 | 1997-10-03 | Колостринин и его применение |
| PL97332632A PL195627B1 (pl) | 1996-10-03 | 1997-10-03 | Zastosowania kolostryniny, kompozycje farmaceutyczne do leczenia przewlekłych chorób ośrodkowego układu nerwowego lub immunostymulacji i zastosowanie nonapeptydu |
| CA2266859A CA2266859C (en) | 1996-10-03 | 1997-10-03 | Colostrinin, and uses thereof |
| GB9908331A GB2333453B (en) | 1996-10-03 | 1997-10-03 | Colostrinin and uses thereof |
| CNA031466095A CN1535722A (zh) | 1996-10-03 | 1997-10-03 | 初乳肽及其用途 |
| PCT/GB1997/002721 WO1998014473A1 (en) | 1996-10-03 | 1997-10-03 | Colostrinin, and uses thereof |
| KR1020057004215A KR20050046766A (ko) | 1996-10-03 | 1997-10-03 | 콜로스트리닌을 포함하는 식품 보조제 |
| IL12921197A IL129211A (en) | 1996-10-03 | 1997-10-03 | Use of colostrinin in the manufacture of a medicament for the treatment of central nervous system disorders |
| CN97198535A CN1131712C (zh) | 1996-10-03 | 1997-10-03 | 初乳肽及其用途 |
| AU45651/97A AU4565197A (en) | 1996-10-03 | 1997-10-03 | Colostrinin, and uses thereof |
| CZ0114999A CZ298215B6 (cs) | 1996-10-03 | 1997-10-03 | Lécivo pro lécení chronických poruch centrálního nervového systému, potravinový doplnek a farmaceutická kompozice, obsahující kolostrinin nebo z nehoodvozený nanopeptid |
| BR9712259-9A BR9712259A (pt) | 1996-10-03 | 1997-10-03 | Colostrininin, uso do mesmo, processos de tratar distúrbios do sistema nervoso central e/ou do sistema imune, de preparar colostrinin de colostro de mamìferos e de produzir uma composição farmacêutica, composição farmacêutica, suplemento dietético, nanopeptìdeo, e, uso do mesmo. |
| KR10-1999-7002904A KR100508764B1 (ko) | 1996-10-03 | 1997-10-03 | 콜로스트리닌을 포함하는 의약품 및 약제학적 조성물 |
| JP10516329A JP2001501929A (ja) | 1996-10-03 | 1997-10-03 | コロストリニン、およびその使用方法 |
| ARP970104585A AR013612A1 (es) | 1996-10-03 | 1997-10-03 | Colostrinina y usos de la misma para la manufactura de un medicamento, una composicion farmaceutica que la comprende, uso de la misma como suplemento dedieta, un suplemento de dieta, un nonapeptido, el uso del mismo para la manufactura de un medicamento, composicion farmaceutica y metodo para prepar |
| EP97944005A EP0932623A1 (en) | 1996-10-03 | 1997-10-03 | Colostrinin, and uses thereof |
| NZ510681A NZ510681A (en) | 1996-10-03 | 1997-10-03 | The use of colostrinin or the nonapeptide in a medicament as in a dietary supplement and in a pharmaceutical composition |
| ZA9708885A ZA978885B (en) | 1996-10-03 | 1997-10-03 | Colostrinin and uses thereof. |
| GB0023325A GB2352176B (en) | 1996-10-03 | 1997-10-03 | Colostrinin and uses thereof |
| HU9904368A HUP9904368A3 (en) | 1996-10-03 | 1997-10-03 | Colostrinin,and uses thereof |
| US09/269,845 US6852700B1 (en) | 1996-10-03 | 1997-10-03 | Colostrinin, and uses thereof |
| US11/003,854 US20050152985A1 (en) | 1996-10-03 | 2004-12-03 | Colostrinin, and uses thereof |
| JP2008031513A JP2008174561A (ja) | 1996-10-03 | 2008-02-13 | コロストリニン、およびその使用方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL96316416A PL185442B1 (pl) | 1996-10-03 | 1996-10-03 | Środek farmaceutyczny o działaniu immunologicznym i psychotropowym, jego postać terapeutyczna oraz zastosowanie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL316416A1 PL316416A1 (en) | 1998-04-14 |
| PL185442B1 true PL185442B1 (pl) | 2003-05-30 |
Family
ID=20068412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL96316416A PL185442B1 (pl) | 1996-10-03 | 1996-10-03 | Środek farmaceutyczny o działaniu immunologicznym i psychotropowym, jego postać terapeutyczna oraz zastosowanie |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6852700B1 (enExample) |
| EP (1) | EP0932623A1 (enExample) |
| JP (2) | JP2001501929A (enExample) |
| KR (2) | KR100508764B1 (enExample) |
| CN (2) | CN1535722A (enExample) |
| AR (1) | AR013612A1 (enExample) |
| AU (1) | AU4565197A (enExample) |
| BR (1) | BR9712259A (enExample) |
| CA (1) | CA2266859C (enExample) |
| CZ (1) | CZ298215B6 (enExample) |
| GB (1) | GB2333453B (enExample) |
| HU (1) | HUP9904368A3 (enExample) |
| IL (1) | IL129211A (enExample) |
| PL (1) | PL185442B1 (enExample) |
| RU (1) | RU2217152C2 (enExample) |
| TR (1) | TR199901022T2 (enExample) |
| WO (1) | WO1998014473A1 (enExample) |
| ZA (1) | ZA978885B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016072871A1 (en) | 2014-11-04 | 2016-05-12 | Geo-Poland Sp. Z.O.O. | Proline-rich polypeptide complex for use in treatment of bdnf-dependent disorders |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL185442B1 (pl) | 1996-10-03 | 2003-05-30 | Georgiades Biotech Ltd | Środek farmaceutyczny o działaniu immunologicznym i psychotropowym, jego postać terapeutyczna oraz zastosowanie |
| BR9910725A (pt) | 1998-05-27 | 2001-01-30 | Gemma Biotechnology Ltd | Indução de proteìnas e peptìdeos antibióticos por proteìnas lait/s cd14 |
| EP1094824B1 (en) * | 1998-06-10 | 2006-04-05 | Albert B. Crum | Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system |
| GB9813031D0 (en) * | 1998-06-16 | 1998-08-12 | Regen Biotech Limited | Dietary supplement |
| GB9912852D0 (en) * | 1999-06-02 | 1999-08-04 | Regen Therapeutics Plc | Peptides |
| AU6917700A (en) * | 1999-08-17 | 2001-03-13 | University Of Texas System, The | Use of colostrinin, constituent peptides thereof, and analogs thereof to promoteneural cell differentiation |
| US6852685B1 (en) * | 1999-08-17 | 2005-02-08 | Board Of Regents, The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof to promote neuronal cell differentiation |
| US7119064B2 (en) | 1999-08-17 | 2006-10-10 | Board Of Regents, The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof as modulators of intracellular signaling molecules |
| EP1224217A4 (en) * | 1999-08-17 | 2006-05-24 | Univ Texas | USE OF COLOSTRININ, THOSE FORMING PEPTIDES, AND ANALOGS FROM INDUCING CYTOKINES |
| US6500798B1 (en) | 1999-08-17 | 2002-12-31 | Board Of Regents, The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof, as oxidative stress regulators |
| US6903068B1 (en) * | 1999-08-17 | 2005-06-07 | Board Of Regents, The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines |
| GB0001825D0 (en) * | 2000-01-26 | 2000-03-22 | Regen Therapeutics Plc | Peptides |
| AU2000269178A1 (en) * | 2000-08-17 | 2002-02-25 | The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof as oxidative stress regulators |
| AU2000267883A1 (en) * | 2000-08-17 | 2002-02-25 | Regen Therapeutics Plc | Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines |
| AU2000269179A1 (en) * | 2000-08-17 | 2002-02-25 | The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof to promoteneural cell differentiation |
| GB0029777D0 (en) * | 2000-12-06 | 2001-01-17 | Regen Therapeutics Plc | Peptides |
| HUP0200172A2 (hu) * | 2002-01-15 | 2003-11-28 | András Bertha | Eljárás tumorellenes hatóanyag kinyerésére |
| EP1567551A4 (en) * | 2002-10-22 | 2008-03-12 | Univ Texas | COLOSTRININ AND PEPTIDES THEREOF AS MODULATORS OF INTRA-CELLULAR SIGNAL MOLECULES AND APOPTOSIS INHIBITORS |
| PL1613648T3 (pl) * | 2003-03-11 | 2008-05-30 | Regen Therapeutics Plc | Oczyszczanie peptydów z siary |
| CN1313487C (zh) * | 2003-06-10 | 2007-05-02 | 天津商学院 | 具有抗菌作用的免疫活性肽（Trpi） |
| WO2005041680A2 (en) * | 2003-11-03 | 2005-05-12 | Advanced Protein Systems | A novel colostral fractionation process |
| EP1723951A1 (en) * | 2005-04-21 | 2006-11-22 | N.V. Nutricia | Nutritional supplement with oligosaccharides for a category of HIV patients |
| US20070212367A1 (en) * | 2006-03-13 | 2007-09-13 | Keech Andrew M | Novel immunologically active peptide fragments of a proline-rich polypeptide isolated from colostral mammalian fluids for treatment of viral and non-viral diseases or diseased conditions |
| GB2436328A (en) * | 2006-03-22 | 2007-09-26 | Regen Therapeutics Plc | Peptide derived from colostrinin |
| US20110098216A1 (en) * | 2009-10-22 | 2011-04-28 | Regen Therapeutics Plc | Therapeutic uses of colostrinin |
| ITMI20111460A1 (it) * | 2011-07-29 | 2013-01-30 | Bionest Ltd | Composizioni per la terapia adiuvante dell'anoressia comprendenti anticorpi, fattori di crescita e citochine isolati dal colostro dei mammiferi |
| EP2797610A1 (en) | 2011-12-30 | 2014-11-05 | BIONEST Ltd. | Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, and chemotactic factors |
| RU2642650C2 (ru) | 2011-12-30 | 2018-01-25 | Инномед С.А. | Комбинация факторов роста, цитокинов, антибактериальных/антивирусных факторов, факторов стволовых клеток, белков комплемента с3а/с4а, иммуноглобулинов и хемотаксических факторов |
| ITMI20112433A1 (it) * | 2011-12-30 | 2013-07-01 | Bionest Ltd | Composizioni per la terapia orale adiuvante dell'anoressia comprendenti anticorpi, antibatterici, fattori di crescita e citochine |
| GB201205856D0 (en) | 2012-04-02 | 2012-05-16 | Randall Jeremy A P | Food supplement to support brain function |
| DE112015005883T5 (de) | 2015-01-30 | 2017-09-28 | Hewlett-Packard Development Company, L.P. | M-äre zyklische codierung |
| WO2020176637A1 (en) | 2019-02-26 | 2020-09-03 | Pantheryx, Inc. | Compositions for management of disorders of the gastrointestinal tract |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE90569T1 (de) | 1988-04-19 | 1993-07-15 | Biotest Pharma Gmbh | Praeparat mit antikoerperaktivitaet und breitem wirkungsspektrum, daraus bestehende oder diese enthaltende mittel und deren verwendung zur behandlung von bakteriell oder toxin-bedingten erkrankungen und zur bekaempfung von protozoen. |
| JPH05163160A (ja) * | 1991-12-13 | 1993-06-29 | Snow Brand Milk Prod Co Ltd | 免疫低下に伴う感染症の予防及び治療用栄養剤 |
| JP3174611B2 (ja) * | 1992-02-28 | 2001-06-11 | 明治乳業株式会社 | 免疫賦活組成物 |
| US5645834A (en) | 1992-08-28 | 1997-07-08 | Immuno-Dynamics, Inc. | Method and product for treating failure of passive transfer and improving milk production in bovine species |
| GB9318611D0 (en) * | 1993-09-08 | 1993-10-27 | Sandoz Nutrition Ltd | Improvements in or relating to organic compounds |
| DE4337654C2 (de) | 1993-11-04 | 1996-08-08 | Biotest Pharma Gmbh | Verwendung boviner Kolostralmilch von nicht mit Viren hyperimmunisierten Tieren als Leberschutzpräparat |
| JP4112021B2 (ja) * | 1994-02-16 | 2008-07-02 | 明治乳業株式会社 | 乳酸菌を用いた免疫賦活剤 |
| RU2062109C1 (ru) * | 1994-11-28 | 1996-06-20 | Товарищество с ограниченной ответственностью "Старк" | Способ получения иммунного препарата |
| AU6641896A (en) | 1995-08-07 | 1997-03-05 | New England Medical Center Hospitals, Inc., The | Infant formula and infant formula additives |
| DE19619990A1 (de) | 1996-05-17 | 1997-11-20 | Charlotte Adler | Verfahren zur Herstellung von Kolostralmilchprodukten sowie deren Verwendung |
| PL185442B1 (pl) | 1996-10-03 | 2003-05-30 | Georgiades Biotech Ltd | Środek farmaceutyczny o działaniu immunologicznym i psychotropowym, jego postać terapeutyczna oraz zastosowanie |
-
1996
- 1996-10-03 PL PL96316416A patent/PL185442B1/pl not_active IP Right Cessation
-
1997
- 1997-10-03 US US09/269,845 patent/US6852700B1/en not_active Expired - Lifetime
- 1997-10-03 CN CNA031466095A patent/CN1535722A/zh active Pending
- 1997-10-03 KR KR10-1999-7002904A patent/KR100508764B1/ko not_active Expired - Fee Related
- 1997-10-03 AR ARP970104585A patent/AR013612A1/es unknown
- 1997-10-03 RU RU99109093/15A patent/RU2217152C2/ru not_active IP Right Cessation
- 1997-10-03 BR BR9712259-9A patent/BR9712259A/pt not_active Application Discontinuation
- 1997-10-03 WO PCT/GB1997/002721 patent/WO1998014473A1/en not_active Ceased
- 1997-10-03 TR TR1999/01022T patent/TR199901022T2/xx unknown
- 1997-10-03 CA CA2266859A patent/CA2266859C/en not_active Expired - Fee Related
- 1997-10-03 EP EP97944005A patent/EP0932623A1/en not_active Withdrawn
- 1997-10-03 CZ CZ0114999A patent/CZ298215B6/cs not_active IP Right Cessation
- 1997-10-03 ZA ZA9708885A patent/ZA978885B/xx unknown
- 1997-10-03 CN CN97198535A patent/CN1131712C/zh not_active Expired - Fee Related
- 1997-10-03 GB GB9908331A patent/GB2333453B/en not_active Expired - Fee Related
- 1997-10-03 AU AU45651/97A patent/AU4565197A/en not_active Abandoned
- 1997-10-03 JP JP10516329A patent/JP2001501929A/ja active Pending
- 1997-10-03 HU HU9904368A patent/HUP9904368A3/hu unknown
- 1997-10-03 KR KR1020057004215A patent/KR20050046766A/ko not_active Ceased
- 1997-10-03 IL IL12921197A patent/IL129211A/en not_active IP Right Cessation
-
2004
- 2004-12-03 US US11/003,854 patent/US20050152985A1/en not_active Abandoned
-
2008
- 2008-02-13 JP JP2008031513A patent/JP2008174561A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016072871A1 (en) | 2014-11-04 | 2016-05-12 | Geo-Poland Sp. Z.O.O. | Proline-rich polypeptide complex for use in treatment of bdnf-dependent disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2333453B (en) | 2001-05-30 |
| GB2333453A (en) | 1999-07-28 |
| IL129211A0 (en) | 2000-02-17 |
| AR013612A1 (es) | 2001-01-10 |
| JP2001501929A (ja) | 2001-02-13 |
| GB9908331D0 (en) | 1999-06-09 |
| RU2217152C2 (ru) | 2003-11-27 |
| US6852700B1 (en) | 2005-02-08 |
| EP0932623A1 (en) | 1999-08-04 |
| PL316416A1 (en) | 1998-04-14 |
| CN1535722A (zh) | 2004-10-13 |
| ZA978885B (en) | 1999-07-26 |
| IL129211A (en) | 2004-08-31 |
| CA2266859A1 (en) | 1998-04-09 |
| CN1131712C (zh) | 2003-12-24 |
| BR9712259A (pt) | 2000-01-25 |
| US20050152985A1 (en) | 2005-07-14 |
| KR20050046766A (ko) | 2005-05-18 |
| CZ298215B6 (cs) | 2007-07-25 |
| KR100508764B1 (ko) | 2005-08-17 |
| WO1998014473A1 (en) | 1998-04-09 |
| KR20000048886A (ko) | 2000-07-25 |
| HUP9904368A2 (hu) | 2000-06-28 |
| GB2333453A8 (en) | 2000-11-27 |
| TR199901022T2 (xx) | 1999-07-21 |
| CN1238782A (zh) | 1999-12-15 |
| HUP9904368A3 (en) | 2000-07-28 |
| CZ114999A3 (cs) | 2000-06-14 |
| CA2266859C (en) | 2012-05-08 |
| AU4565197A (en) | 1998-04-24 |
| JP2008174561A (ja) | 2008-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2266859C (en) | Colostrinin, and uses thereof | |
| JP4416839B2 (ja) | 二次性免疫不全症の治療法 | |
| Yoshida et al. | Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors | |
| Yamasaki et al. | Specific adoptive immunotherapy with tumor-specific cytotoxic T-lymphocyte clone for murine malignant gliomas | |
| JPH05509093A (ja) | インターロイキン―７を用いた選定免疫療法 | |
| JP5247429B2 (ja) | カゼイン由来ペプチドを含む医薬組成物及びその使用方法 | |
| FR2537436A1 (fr) | Procede de regulation de l'appetit et de l'efficacite de l'utilisation des aliments utilisant de l'interferon | |
| Wang et al. | Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2 | |
| Saijo et al. | Analysis of metastatic spread and growth of tumor cells in mice with depressed natural killer activity by anti-asialo GMl antibody or anticancer agents | |
| WO2005018542A2 (en) | Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects | |
| PT99123B (pt) | Processo para a preparacao de uma composicao farmaceutica contendo o factor de necrose de tumor e interleuquina-4 | |
| US9222072B2 (en) | Manufacturing method of immune killer cells | |
| JPH02111727A (ja) | 免疫反応が減少したときの免疫系のためのインターロイキン―２の使用 | |
| JP3492671B2 (ja) | 免疫アジュバント | |
| CN112007140A (zh) | 脾氨肽在制备治疗肠屏障功能缺损的药物中的应用 | |
| AU761148B2 (en) | Colostrinin, and uses thereof | |
| Bowers et al. | The effect of silica treatment on accessory cell-dependent rat T lymphocyte proliferation | |
| GB2352176A (en) | Colostrinin and uses thereof | |
| PL195627B1 (pl) | Zastosowania kolostryniny, kompozycje farmaceutyczne do leczenia przewlekłych chorób ośrodkowego układu nerwowego lub immunostymulacji i zastosowanie nonapeptydu | |
| Meneses et al. | Thymostimulin increases natural cytotoxic activity in patients with breast cancer | |
| Igarashi et al. | Induction of the differentiation of memory T killer cells with factors released from macrophage-like cell lines | |
| MXPA99003108A (en) | Colostrinin, and uses thereof | |
| EP0444691A1 (en) | Use of interleukin-1 to enhance the immune response of weakly immunogenic tumors | |
| Moroz et al. | Treatment of patients with transitional cell carcinoma of the urinary bladder with intravesical poly I: Poly C effects on natural killer function | |
| Nakano et al. | Tochigiken, Japan and Department of Bacteriology Tohoku Dental University, Koriyama, Japan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20091003 |